|
|
|
|
|
|
|
M T Wed Th F |
|
29 April, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
Andrew Dunn has a dispatch from his time in Brazil, in which he talked to Kyunghyun Cho, an AI researcher who recently left big pharma. One quote, about the impact of AI on healthcare and his work at Genentech, stuck out to me: "Because of how the healthcare system is designed, the consequences are incremental. There was a technological leap there, but the consequences of this leap had to be incremental, because we are so far away from the patients who will benefit from whatever comes out of it.” Read the full story here.
|
|
|
|
Lydia Ramsey Pflanzer |
Deputy Editor, Endpoints News
|
|
|
|
 |
|
Kyunghyun Cho speaking at Endpoints AI Day 2024 (Endpoints News photo) |
|
|
|
by Andrew Dunn
|
RIO DE JANEIRO — Kyunghyun Cho says he's a free man once again. He makes that observation, semi-jokingly, while looking over countless rows of poster... | |
|
|
|
|
|
|
by Max Bayer
|
The FDA is set to convene its first advisory meeting of oncology experts in about nine months, with a couple of AstraZeneca drugs as the... | |
|
|
|
|
|
|
by Max Gelman
|
Threats to AbbVie's immunology dominance took center stage on the company's first-quarter earnings call Wednesday morning, as analysts pressed executives on their defense strategy. The... | |
|
|
|
|
|
 |
| . |
|
Chris Boerner, Bristol Myers Squibb CEO (Kevin Dietsch/Getty Images) |
 |
|
|
|
by Max Gelman
|
Bristol Myers Squibb is facing a bit of an identity crisis. CEO Chris Boerner is nearly two and a half years into his tenure, with... | |
|
|
|
|
|
|
by Elizabeth Cairns
|
AstraZeneca said it had stopped several mid- and late-stage trials of some of its pipeline programs in the past few months, potentially limiting some of... | |
|
|
|
|
|
